Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP993277priorityCriticalpatent/ECSP993277A/en
Publication of ECSP993277ApublicationCriticalpatent/ECSP993277A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
4,5-azolo-oxindoles nuevos con la fórmula (gráfico), donde R1, R2, Y, Z ya tienen el significado indicado en la especificación, inhiben las quinasas dependientes de ciclina (CDKs), en partcular CDK2, y son útiles en el tratamiento o control de los desórdenes proliferativos celulares, en particular el cáncer.New 4,5-azolo-oxindoles with the formula (graph), where R1, R2, Y, Z already have the meaning indicated in the specification, inhibit cyclin-dependent kinases (CDKs), in particular CDK2, and are useful in the treatment or control of cellular proliferative disorders, in particular cancer.
3,4-DIHYDRO-1H-PYRIMIDE [4,5-D] PYRIMIDIN-2-ONE 1,5-DISUBTITUTED COMPOUNDS AND THEIR USE FOR THE THERAPEUTIC TREATMENT OF DISEASES MEDIATED BY CSBP/P38 KINASE
PHARMACEUTICAL COMBINATION THAT INCLUDES 8A) MELATONIN AND MELATONINE AGONISTS, AND NICOTINE AND NICOTINE RECEIVING AGONISTS; PHARMACEUTICAL KIT, AND; USE IN THE TREATMENT OF INSOMNIUM, COGNITIVE DIFFICULTIES AND MEMORY DIFFICULTIES; FARMACEU KIT